미국 · 보도자료 · NTRA · 2026-10-05 12:00
유방암 대상 Signatera 기반 임상 3상 글로벌 시험 발표
BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment
